Compare AJANTA PHARMA with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA IPCA LABS AJANTA PHARMA/
IPCA LABS
 
P/E (TTM) x 24.4 24.6 99.4% View Chart
P/BV x 6.8 8.8 77.2% View Chart
Dividend Yield % 0.5 0.1 376.7%  

Financials

 AJANTA PHARMA   IPCA LABS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
IPCA LABS
Mar-19
AJANTA PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs1,4221,042 136.5%   
Low Rs898590 152.1%   
Sales per share (Unadj.) Rs233.5298.6 78.2%  
Earnings per share (Unadj.) Rs44.035.0 125.6%  
Cash flow per share (Unadj.) Rs52.249.4 105.5%  
Dividends per share (Unadj.) Rs9.003.00 300.0%  
Dividend yield (eoy) %0.80.4 211.1%  
Book value per share (Unadj.) Rs255.1247.1 103.2%  
Shares outstanding (eoy) m88.02126.35 69.7%   
Bonus/Rights/Conversions BBESOS-  
Price / Sales ratio x5.02.7 181.7%   
Avg P/E ratio x26.423.3 113.1%  
P/CF ratio (eoy) x22.216.5 134.7%  
Price / Book Value ratio x4.53.3 137.7%  
Dividend payout %20.58.6 238.8%   
Avg Mkt Cap Rs m102,081103,108 99.0%   
No. of employees `0006.813.4 50.6%   
Total wages/salary Rs m4,3077,874 54.7%   
Avg. sales/employee Rs Th3,022.62,807.0 107.7%   
Avg. wages/employee Rs Th633.4585.8 108.1%   
Avg. net profit/employee Rs Th569.1329.0 173.0%   
INCOME DATA
Net Sales Rs m20,55437,732 54.5%  
Other income Rs m211577 36.5%   
Total revenues Rs m20,76538,309 54.2%   
Gross profit Rs m5,6646,901 82.1%  
Depreciation Rs m7211,824 39.5%   
Interest Rs m12189 6.1%   
Profit before tax Rs m5,1435,465 94.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2731,042 122.1%   
Profit after tax Rs m3,8704,422 87.5%  
Gross profit margin %27.618.3 150.7%  
Effective tax rate %24.819.1 129.8%   
Net profit margin %18.811.7 160.6%  
BALANCE SHEET DATA
Current assets Rs m11,81223,778 49.7%   
Current liabilities Rs m3,77610,975 34.4%   
Net working cap to sales %39.133.9 115.2%  
Current ratio x3.12.2 144.4%  
Inventory Days Days77104 74.6%  
Debtors Days Days8266 123.8%  
Net fixed assets Rs m14,39820,368 70.7%   
Share capital Rs m175253 69.4%   
"Free" reserves Rs m22,27730,971 71.9%   
Net worth Rs m22,45231,224 71.9%   
Long term debt Rs m71,409 0.5%   
Total assets Rs m26,96245,507 59.2%  
Interest coverage x444.330.0 1,483.1%   
Debt to equity ratio x00 0.7%  
Sales to assets ratio x0.80.8 91.9%   
Return on assets %14.410.1 142.1%  
Return on equity %17.214.2 121.7%  
Return on capital %23.017.3 132.5%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m10,68217,308 61.7%   
Fx outflow Rs m2,1026,266 33.5%   
Net fx Rs m8,58011,042 77.7%   
CASH FLOW
From Operations Rs m3,7484,923 76.1%  
From Investments Rs m-2,228-1,563 142.5%  
From Financial Activity Rs m-1,475-1,832 80.5%  
Net Cashflow Rs m451,528 3.0%  

Share Holding

Indian Promoters % 73.8 45.9 160.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 11.4 13.6%  
FIIs % 7.6 25.3 30.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 17.4 97.7%  
Shareholders   20,968 36,892 56.8%  
Pledged promoter(s) holding % 4.4 2.1 205.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  GSK PHARMA  UNICHEM LAB  ORCHID PHARMA  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 883 Points Today(Closing)

Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Apr 19, 2021 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - SUVEN LIFE SCIENCES COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS